DarioHealth (NASDAQ:DRIO) Upgraded at ValuEngine
DarioHealth (NASDAQ:DRIO) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.
DRIO opened at $5.01 on Tuesday. DarioHealth has a 1-year low of $3.44 and a 1-year high of $18.60. The stock’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $0.67. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.35 and a current ratio of 1.70.
DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. DarioHealth had a negative return on equity of 325.50% and a negative net margin of 248.57%. The business had revenue of $1.87 million for the quarter.
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Recommended Story: What is the Nikkei 225 index?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.